News from acelrx pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 10, 2023, 16:05 ET AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Apr 27, 2023, 16:05 ET AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

Apr 05, 2023, 08:30 ET AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Mar 30, 2023, 16:05 ET AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program ...

Mar 21, 2023, 16:05 ET AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

Mar 14, 2023, 08:30 ET AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up...

Mar 01, 2023, 08:30 ET AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Dec 27, 2022, 08:30 ET AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Dec 08, 2022, 08:30 ET AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Nov 14, 2022, 16:01 ET AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Nov 03, 2022, 08:30 ET AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter...

Oct 31, 2022, 08:30 ET AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 27, 2022, 08:30 ET AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 26, 2022, 08:30 ET AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 25, 2022, 16:42 ET AcelRx Pharmaceuticals Announces Reverse Stock Split

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 25, 2022, 08:30 ET AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Sep 06, 2022, 16:30 ET AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of...

Aug 25, 2022, 08:30 ET AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Aug 11, 2022, 16:01 ET AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth...

Aug 11, 2022, 08:30 ET AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Aug 10, 2022, 08:30 ET AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Jul 28, 2022, 16:50 ET AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial...

May 20, 2022, 12:49 ET AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of...

May 19, 2022, 08:30 ET AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of...

May 16, 2022, 07:30 ET AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual...